The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies-Reference-Cited by-同舟云学术

The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies

Published:1999-12 Issue:5 Volume:45 Page:1143-1149
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Movsas Benjamin,Scott Charles,Sause William,Byhardt Roger,Komaki Ritsuko,Cox James,Johnson Douglas,Lawton Colleen,Dar A.Rashid,Wasserman Todd,Roach Mack,Lee J.S.,Andras Ellis

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference23 articles.

1. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine;Murray;Int J Radiat Oncol Biol Phys,1995

2. Intensified treatment increases survival in patients with non-small cell lung cancer (NSCLC) at what price? A quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemo-radiation studies;Scott;Quality of Life Research,1997

3. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60 Gy to 792 Gy;Cox;J Clin Oncol,1990

4. Radiation therapy oncology group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588;Sause;J Natl Cancer Inst,1995

5. Phase II trial of combination chemotherapy and irradiation in nonsmall cell lung cancer. Radiation Therapy Oncology Group 88-04;Sause;Am J Clin Oncol,1992

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer;Frontiers in Pharmacology;2023-01-12

2. Multimodality Treatment with Radiotherapy and Immunotherapy in Older Adults: Rationale, Evolving Data, and Current Recommendations;Seminars in Radiation Oncology;2022-04

3. Non-Small Cell Lung Cancer in Older Adults with Frailty;Frailty in Older Adults with Cancer;2022

4. Radiation Therapy for Lung Cancer in Elderly;Medical Radiology;2022

5. Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy;Cancers;2021-09-09